[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Citius Oncology Inc (CTOR)

Citius Oncology Inc (CTOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 78,095
  • Shares Outstanding, K 92,981
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,760 K
  • EBIT $ -44 M
  • EBITDA $ -44 M
  • 60-Month Beta 3.56
  • Price/Sales 12.56
  • Price/Cash Flow N/A
  • Price/Book 2.07
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.47
  • Most Recent Earnings $-0.27 on 05/15/26
  • Next Earnings Date 08/11/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7501 +11.97%
on 05/18/26
0.9995 -15.97%
on 04/23/26
-0.0999 (-10.63%)
since 04/22/26
3-Month
0.4912 +70.99%
on 03/30/26
1.1750 -28.52%
on 02/23/26
-0.3201 (-27.59%)
since 02/20/26
52-Week
0.4912 +70.99%
on 03/30/26
6.1900 -86.43%
on 06/27/25
-0.0701 (-7.70%)
since 05/22/25

Most Recent Stories

More News
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR ®

CTXR : 0.7011 (+4.16%)
CTOR : 0.8399 (+1.31%)
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR ® launch progresses Up to $36.5 million in debt and equity capital secured Broad...

CTXR : 0.7011 (+4.16%)
CTOR : 0.8399 (+1.31%)
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

Avenue Capital Group to provide up to $25 Million via Senior Credit Facility with an initial $10 million tranche funded at closing; additional tranches subject to certain conditions

CTOR : 0.8399 (+1.31%)
Citius Oncology Ships First International Order of LYMPHIRâ„¢ to Europe

Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch

CTXR : 0.7011 (+4.16%)
CTOR : 0.8399 (+1.31%)
Citius Oncology Provides Commercial Update on LYMPHIRâ„¢ Launch Highlighting Early Adoption and Expanding Clinical Development

Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integration

CTXR : 0.7011 (+4.16%)
CTOR : 0.8399 (+1.31%)
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIRâ„¢ in Discussions with Leading Cutaneous Lymphoma Experts

Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinical engagement; one-on-one meetings available

CTXR : 0.7011 (+4.16%)
CTOR : 0.8399 (+1.31%)
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy

CTXR : 0.7011 (+4.16%)
CTOR : 0.8399 (+1.31%)
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma

Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response...

CTOR : 0.8399 (+1.31%)
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIRâ„¢

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results

CTXR : 0.7011 (+4.16%)
CTOR : 0.8399 (+1.31%)
Citius Oncology Expands International Distribution of LYMPHIRâ„¢ to European Union Through Exclusive Agreement with Uniphar

Third international distribution agreement further advances global access strategy with major markets in Europe

CTXR : 0.7011 (+4.16%)
CTOR : 0.8399 (+1.31%)

Business Summary

Citius Oncology Inc. platform to develop and commercialize novel targeted oncology therapies. The company is seeking approval from the U.S. Food and Drug Administration of LYMPHIR(TM) for an orphan indication in the treatment of persistent or recurrent cutaneous T-cell lymphoma, a rare form of non-Hodgkin...

See More

Key Turning Points

3rd Resistance Point 0.9010
2nd Resistance Point 0.8705
1st Resistance Point 0.8552
Last Price 0.8399
1st Support Level 0.8094
2nd Support Level 0.7789
3rd Support Level 0.7636

See More

52-Week High 6.1900
Fibonacci 61.8% 4.0131
Fibonacci 50% 3.3406
Fibonacci 38.2% 2.6681
Last Price 0.8399
52-Week Low 0.4912

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.